1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

EMPRISE studies the comparative effectiveness, safety and health care resource utilization of empagliflozin (EMPA) in Medicare and 2 U.S. commercial claims datasets (2014-2019). In this first analysis, we evaluated healthcare costs and medications burden associated with EMPA vs. dipeptidyl peptidase 4 inhibitors (DPP-4i) use in routine care patients with type 2 diabetes (T2D). We identified a 1:1 propensity-score-matched cohort of T2D patients ≥18 years initiating either EMPA or DPP-4i between 08/2014-09/2016. Total (inpatient, outpatient, pharmacy) cost and medication burden were compared for EMPA vs. DPP-4i. We identified 17,549 matched pairs with balanced baseline characteristics (Table 1) with mean follow-up of 5.4 months. Per member per year (PMPY) total cost was similar among EMPA vs. DDP4i initiators ($17,771 vs. $17,814; Diff= -$43, 95% CI: -1,380─1,295). Medical costs tended to be lower and pharmacy costs were higher in EMPA initiators. Distinct medication prescriptions were slightly lower among EMPA initiators [Incidence rate ratio 0.97, 95% CI: 0.96─0.98]. Results stratified by history of CV disease were consistent. Within the first two years of EMPRISE, we observed similar total cost, driven by trend towards lower medical and higher pharmacy costs, and lower medication burden in EMPA vs. DDP4i initiators. Disclosure A. Pawar: None. E. Patorno: Research Support; Self; National Institute on Aging. Other Relationship; Self; Boehringer Ingelheim International GmbH. A. Deruaz-Luyet: Employee; Self; Boehringer Ingelheim International GmbH. Employee; Spouse/Partner; Medtronic, Sanofi. K. Brodovicz: Employee; Self; Boehringer Ingelheim Pharmaceuticals, Inc. A.V. Ustyugova: Employee; Self; Boehringer Ingelheim International GmbH. N. Gautam: None. L.G. Bessette: None. S. Schneeweiss: Consultant; Self; Aetion, WHISCON, LLC. M. Najafzadeh: Consultant; Self; Epigenomics. Funding Boehringer Ingelheim